The Combination of Genistein andImatinib has an Increased Effect on Cell Proliferation Inhibition in Philadelphia Positive Leukemia Cell Lines

Background: Introduction:This study investigated the possible role of Genistein as a combination with Imatinib in controlling leukemia cell line proliferation. Methods: Three cell lines, K562, Kcl22, and CCRF, were cultured and analyzed for MTT, LDH, apoptosis, and cycle cell gene expression in the presence of different dosages of Imatinib and Genistein in combination or separately. Results: Data has shown a decrease in proliferation and an increase in apoptosis activity during combination treatment. LDH assay has shown no additional toxicity due to Genistein consumption in combination therapy. Analysis of the expression of responsible genes for cell cycle demonstrated both G1 (p53, p21 upregulation) and G2 (cdc25c downregulation) inhibitory effect in combination treatment. Conclusion: Altogether, this study suggests thatthe combination treatment of Imatinib and Genistein for leukemia cells resistant to Imatinib can increase treatment efficiency.

[1]  F. F. de Melo,et al.  Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review , 2021, World journal of clinical oncology.

[2]  E. Karaca,et al.  How Far Are We from the Rapid Prediction of Drug Resistance Arising Due to Kinase Mutations? , 2021, ACS omega.

[3]  A. Vologzhanina,et al.  Intermolecular Interactions in Crystal Structures of Imatinib-Containing Compounds , 2020, International journal of molecular sciences.

[4]  S. Krähenbühl,et al.  Imatinib and Dasatinib Provoke Mitochondrial Dysfunction Leading to Oxidative Stress in C2C12 Myotubes and Human RD Cells , 2020, Frontiers in Pharmacology.

[5]  J. Fish,et al.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia , 2020, Current Hematologic Malignancy Reports.

[6]  A. Serafino,et al.  Nature-derived compounds modulating Wnt/β-catenin pathway: a preventive and therapeutic opportunity in neoplastic diseases , 2020, Acta pharmaceutica Sinica. B.

[7]  Ximing J. Yang,et al.  Genistein treatment duration effects biomarkers of cell motility in human prostate , 2019, PloS one.

[8]  S. Uddin,et al.  Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products , 2018, Molecular Cancer.

[9]  G. Martinelli,et al.  Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy , 2018, Molecular Cancer.

[10]  L. Baroni,et al.  Soy, Soy Foods and Their Role in Vegetarian Diets , 2018, Nutrients.

[11]  E. Ratovitski.  Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression , 2017, Current genomics.

[12]  D. White,et al.  ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines , 2016, PloS one.

[13]  William H. Bisson,et al.  Causes of genome instability: the effect of low dose chemical exposures in modern society. , 2015, Carcinogenesis.

[14]  Kyung-Chul Choi,et al.  Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models , 2014, Laboratory animal research.

[15]  Michael R. Green,et al.  A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia , 2014, Science Translational Medicine.

[16]  Wancai Yang,et al.  Soy isoflavones and prostate cancer: A review of molecular mechanisms , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  A. Nagler,et al.  Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.

[18]  J. Goldman,et al.  [History of chronic myeloid leukemia: a paradigm in the treatment of cancer]. , 2014, Bulletin du cancer.

[19]  Xin Dong,et al.  Combination of low dose of genistein and daidzein has synergistic preventive effects on isogenic human prostate cancer cells when compared with individual soy isoflavone. , 2013, Food chemistry.

[20]  Benoît Roux,et al.  Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases. , 2013, Journal of the American Chemical Society.

[21]  Yun-Kyoung Lee,et al.  Soybean isoflavone genistein regulates apoptosis through NF-κB dependent and independent pathways. , 2013, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[22]  C. Schiffer,et al.  Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized? , 2012, Expert review of hematology.

[23]  Guangchuang Yu,et al.  Genistein‐induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study , 2012, Proteomics.

[24]  Pokharel Manisha,et al.  Leukemia: a review article , 2012 .

[25]  M. Priault,et al.  Mycophenolic Acid Overcomes Imatinib and Nilotinib Resistance of Chronic Myeloid Leukemia Cells by Apoptosis or a Senescent-Like Cell Cycle Arrest , 2012, Leukemia research and treatment.

[26]  D. Nowak,et al.  Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration. , 2011, European journal of pharmacology.

[27]  T. Clackson,et al.  Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia , 2010, Clinical Cancer Research.

[28]  A. Haslberger,et al.  Epigenetic Control of Estrogen Receptor Expression and Tumor Suppressor Genes Is Modulated by Bioactive Food Compounds , 2010, Annals of Nutrition and Metabolism.

[29]  Y. Bignon,et al.  AKT and p 21 WAF 1 / CIP 1 as Potential Genistein Targets in BRCA 1-mutant Human Breast Cancer Cell Lines , 2010 .

[30]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.

[31]  N. Banik,et al.  Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification , 2010, Investigational New Drugs.

[32]  B. Turcq,et al.  Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. , 2008, Cancer research.

[33]  E. de Blas,et al.  Genistein selectively potentiates arsenic trioxide‐induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species‐inducible protein kinases (p38‐MAPK, AMPK) , 2008, International journal of cancer.

[34]  Hasan Mukhtar,et al.  Apoptosis by dietary factors: the suicide solution for delaying cancer growth. , 2006, Carcinogenesis.

[35]  J. Melo,et al.  Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia , 2007, Leukemia.

[36]  I. Ismail,et al.  Genistein Induces G 2 / M Cell Cycle Arrest and Apoptosis in Rat Neuroblastoma B 35 Cells , 2006 .